Alto Neuroscience (NYSE:ANRO) PT Lowered to $10.00 at Robert W. Baird

Alto Neuroscience (NYSE:ANRO) had its price target decreased by Robert W. Baird from $32.00 to $10.00 in a report published on Wednesday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other analysts also recently commented on ANRO. Rodman & Renshaw downgraded Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Finally, Wedbush restated an “outperform” rating and set a $29.00 price objective on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.40.

Alto Neuroscience Stock Performance

ANRO stock opened at $4.36 on Wednesday. The company has a 50-day simple moving average of $12.02 and a 200 day simple moving average of $12.36. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience has a fifty-two week low of $3.93 and a fifty-two week high of $24.00.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.07. As a group, research analysts predict that Alto Neuroscience will post -2.63 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. purchased a new position in Alto Neuroscience during the 1st quarter worth approximately $21,267,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Alto Neuroscience during the first quarter valued at $9,788,000. Vanguard Group Inc. acquired a new position in Alto Neuroscience during the first quarter valued at $8,233,000. Jennison Associates LLC acquired a new position in Alto Neuroscience during the first quarter valued at $7,039,000. Finally, Artal Group S.A. acquired a new stake in Alto Neuroscience during the 1st quarter worth about $5,372,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.